| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
13,590,000 |
| Market
Cap: |
121.77(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$4.02 - $9.54 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Actinium Pharmaceuticals is a clinical-stage, biopharmaceutical company applying its proprietary platform technology and understanding of radiobiology to the development of targeted radiotherapies for patients with unmet needs. Co.'s clinical pipeline is focused on targeting the antigens CD45 and CD33. Iomab-B (I-131 apamistamab), Co.'s primary candidate and targeted conditioning agent is comprised of the anti-CD45 monoclonal antibody known as apamistamab and the radioisotope Iodine-131. Co.'s CD33 program is evaluating the clinical utility of Actimab-A, comprised of the anti-CD33 mAb lintuzumab linked to the potent alpha-emitting radioisotope Actinium-225.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Seth Sandesh |
Chief Executive Officer |
• • – |
2022-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
305,381 |
|
- |
|
| Berger Mark Stanley |
Chief Medical Officer |
• – – |
2019-03-05 |
4 |
OE |
$0.60 |
$2,100 |
D/D |
3,500 |
22,500 |
|
- |
|
| Seth Sandesh |
Chairman & CEO |
• • – |
2019-02-21 |
4 |
OE |
$0.60 |
$4,875 |
D/D |
8,125 |
161,458 |
|
- |
|
| Seth Sandesh |
Chairman & CEO |
• • – |
2018-12-10 |
4 |
B |
$0.44 |
$4,372 |
D/D |
10,000 |
153,333 |
2.73 |
- |
|
| Oloughlin Steve |
Principal Financial Officer |
• – – |
2018-12-10 |
4 |
B |
$0.44 |
$4,350 |
D/D |
10,000 |
35,500 |
2.66 |
- |
|
| Ludwig Dale L. |
Chief Scientific Officer |
• – – |
2018-11-19 |
4 |
B |
$0.45 |
$4,499 |
D/D |
10,000 |
10,000 |
2.66 |
- |
|
| Seth Sandesh |
CEO |
• • – |
2018-07-17 |
4 |
B |
$0.79 |
$7,900 |
D/D |
10,000 |
143,333 |
2.81 |
- |
|
| Oloughlin Steve |
Principal Financial Officer |
• – – |
2018-06-15 |
4 |
B |
$0.50 |
$6,000 |
D/D |
12,000 |
25,500 |
2.74 |
- |
|
| Seth Sandesh |
Chairman & CEO |
• • – |
2018-04-19 |
4 |
B |
$0.38 |
$1,900 |
D/D |
5,000 |
133,333 |
2.73 |
- |
|
| Berger Mark Stanley |
Chief Medical Officer |
• – – |
2018-03-06 |
4 |
A |
$0.50 |
$7,000 |
D/D |
14,000 |
19,000 |
|
- |
|
| Ray Nitya G. |
Executive VP |
• – – |
2018-03-06 |
4 |
A |
$0.50 |
$5,000 |
D/D |
10,000 |
20,000 |
|
- |
|
| Steinhart Richard I |
Director |
– • – |
2018-03-06 |
4 |
A |
$0.50 |
$3,500 |
D/D |
7,000 |
9,500 |
|
- |
|
| Seth Sandesh |
Chairman & CEO |
• • – |
2018-03-06 |
4 |
A |
$0.50 |
$26,250 |
D/D |
52,500 |
128,333 |
|
- |
|
| Oloughlin Steve |
Principal Financial Officer |
• – – |
2018-03-06 |
4 |
A |
$0.50 |
$5,000 |
D/D |
10,000 |
13,500 |
|
- |
|
| Shetty Ajit |
Director |
– • – |
2018-02-28 |
4 |
B |
$0.43 |
$9,774 |
D/D |
22,730 |
22,730 |
2.39 |
- |
|
| Ray Nitya G. |
Executive Vice President |
• – – |
2017-08-02 |
4 |
B |
$0.75 |
$7,500 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Seth Sandesh |
Chairman & CEO |
• • – |
2017-08-02 |
4 |
B |
$0.75 |
$25,000 |
D/D |
33,333 |
75,833 |
2.81 |
- |
|
| Berger Mark Stanley |
Chief Medical Officer |
• – – |
2017-06-15 |
4 |
B |
$1.11 |
$5,550 |
D/D |
5,000 |
5,000 |
2.74 |
- |
|
| Seth Sandesh |
Chairman and CEO |
• • – |
2017-06-15 |
4 |
B |
$1.16 |
$8,725 |
D/D |
7,500 |
42,500 |
2.81 |
- |
|
| Oloughlin Steve |
Principal Financial Officer |
• – – |
2017-06-15 |
4 |
B |
$1.17 |
$4,095 |
D/D |
3,500 |
3,500 |
2.66 |
- |
|
| Seth Sandesh |
Executive Chairman |
• • – |
2016-12-30 |
4 |
B |
$0.88 |
$4,400 |
D/D |
5,000 |
35,000 |
2.73 |
- |
|
| Seth Sandesh |
Executive Chairman |
• • – |
2016-12-12 |
4 |
B |
$0.98 |
$4,900 |
D/D |
5,000 |
30,000 |
2.73 |
- |
|
| Memorial Sloan-Kettering Cancer Center |
10% Owner |
– – • |
2016-08-31 |
4 |
S |
$1.80 |
$251,118 |
D/D |
(136,853) |
4,709,561 |
|
- |
|
| Memorial Sloan-Kettering Cancer Center |
10% Owner |
– – • |
2016-08-30 |
4 |
S |
$1.80 |
$101,254 |
D/D |
(56,074) |
4,846,414 |
|
- |
|
| Memorial Sloan-Kettering Cancer Center |
10% Owner |
– – • |
2016-08-29 |
4 |
S |
$1.71 |
$42,875 |
D/D |
(25,000) |
4,902,488 |
|
- |
|
60 Records found
|
|
Page 1 of 3 |
|
|
0.21 (2.4%) 
